Tags

Type your tag names separated by a space and hit enter

Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial.
Br J Nutr. 2016 07; 116(2):360-74.BJ

Abstract

Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in overweight and obese volunteers. In two randomised-controlled trials, fifty-five volunteers (age: 31 (95 % CI 27, 35) years), BMI: 28·0 (95 % CI 27·3, 28·7) kg/m2) consumed a test meal containing low (44 g), medium (88 g) or high (132 g) mycoprotein or isoenergetic chicken meals. Visual analogue scales and blood samples were collected to measure appetite, glucose, insulin, peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Ad libitum energy intake was assessed after 3 h in part A (n 36). Gastric emptying by the paracetamol method, resting energy expenditure and substrate oxidation were recorded in part B (n 14). Metabonomics was used to compare plasma and urine samples in response to the test meals. Mycoprotein reduced energy intake by 10 % (280 kJ (67 kcal)) compared with chicken at the high content (P=0·009). All mycoprotein meals reduced insulin concentrations compared with chicken (incremental AUClow (IAUClow): -8 %, IAUCmedium: -12 %, IAUChigh: -21 %, P=0·004). There was no significant difference in glucose, PYY, GLP-1, gastric emptying rate and energy expenditure. Following chicken intake, paracetamol-glucuronide was positively associated with fullness. After mycoprotein, creatinine and the deamination product of isoleucine, α-keto-β-methyl-N-valerate, were inversely related to fullness, whereas the ketone body, β-hydroxybutyrate, was positively associated. In conclusion, mycoprotein reduces energy intake and insulin release in overweight volunteers. The mechanism does not involve changes in PYY and GLP-1. The metabonomics analysis may bring new understanding to the appetite regulatory properties of food.

Authors+Show Affiliations

1Nutrition and Dietetics Research Group,Department of Medicine,Division of Diabetes, Endocrinology and Metabolism,Imperial College London,Hammersmith Campus,London W12 0NN,UK.2Division of Computational and Systems Medicine,Department of Surgery and Cancer,Imperial College London, South Kensington Campus,London SW7 2AZ,UK.1Nutrition and Dietetics Research Group,Department of Medicine,Division of Diabetes, Endocrinology and Metabolism,Imperial College London,Hammersmith Campus,London W12 0NN,UK.1Nutrition and Dietetics Research Group,Department of Medicine,Division of Diabetes, Endocrinology and Metabolism,Imperial College London,Hammersmith Campus,London W12 0NN,UK.1Nutrition and Dietetics Research Group,Department of Medicine,Division of Diabetes, Endocrinology and Metabolism,Imperial College London,Hammersmith Campus,London W12 0NN,UK.3Division of Diabetes, Endocrinology and Metabolism,Department of Medicine,Imperial College London,Hammersmith Campus,London W12 0NN,UK.1Nutrition and Dietetics Research Group,Department of Medicine,Division of Diabetes, Endocrinology and Metabolism,Imperial College London,Hammersmith Campus,London W12 0NN,UK.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27198187

Citation

Bottin, Jeanne H., et al. "Mycoprotein Reduces Energy Intake and Postprandial Insulin Release Without Altering Glucagon-like Peptide-1 and Peptide Tyrosine-tyrosine Concentrations in Healthy Overweight and Obese Adults: a Randomised-controlled Trial." The British Journal of Nutrition, vol. 116, no. 2, 2016, pp. 360-74.
Bottin JH, Swann JR, Cropp E, et al. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial. Br J Nutr. 2016;116(2):360-74.
Bottin, J. H., Swann, J. R., Cropp, E., Chambers, E. S., Ford, H. E., Ghatei, M. A., & Frost, G. S. (2016). Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial. The British Journal of Nutrition, 116(2), 360-74. https://doi.org/10.1017/S0007114516001872
Bottin JH, et al. Mycoprotein Reduces Energy Intake and Postprandial Insulin Release Without Altering Glucagon-like Peptide-1 and Peptide Tyrosine-tyrosine Concentrations in Healthy Overweight and Obese Adults: a Randomised-controlled Trial. Br J Nutr. 2016;116(2):360-74. PubMed PMID: 27198187.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial. AU - Bottin,Jeanne H, AU - Swann,Jonathan R, AU - Cropp,Eleanor, AU - Chambers,Edward S, AU - Ford,Heather E, AU - Ghatei,Mohammed A, AU - Frost,Gary S, Y1 - 2016/05/20/ PY - 2016/5/21/entrez PY - 2016/5/21/pubmed PY - 2017/5/18/medline KW - Appetite hormones KW - Energy intake KW - GAA guanidinoacetic acid KW - GI gastrointestinal KW - GLP-1 glucagon-like peptide-1 KW - Gastric emptying KW - IAUC incremental AUC KW - Metabonomics KW - Mycoprotein KW - Obesity KW - Overweight KW - PYY peptide tyrosine-tyrosine KW - REE resting energy expenditure KW - T2DM type 2 diabetes mellitus SP - 360 EP - 74 JF - The British journal of nutrition JO - Br J Nutr VL - 116 IS - 2 N2 - Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in overweight and obese volunteers. In two randomised-controlled trials, fifty-five volunteers (age: 31 (95 % CI 27, 35) years), BMI: 28·0 (95 % CI 27·3, 28·7) kg/m2) consumed a test meal containing low (44 g), medium (88 g) or high (132 g) mycoprotein or isoenergetic chicken meals. Visual analogue scales and blood samples were collected to measure appetite, glucose, insulin, peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Ad libitum energy intake was assessed after 3 h in part A (n 36). Gastric emptying by the paracetamol method, resting energy expenditure and substrate oxidation were recorded in part B (n 14). Metabonomics was used to compare plasma and urine samples in response to the test meals. Mycoprotein reduced energy intake by 10 % (280 kJ (67 kcal)) compared with chicken at the high content (P=0·009). All mycoprotein meals reduced insulin concentrations compared with chicken (incremental AUClow (IAUClow): -8 %, IAUCmedium: -12 %, IAUChigh: -21 %, P=0·004). There was no significant difference in glucose, PYY, GLP-1, gastric emptying rate and energy expenditure. Following chicken intake, paracetamol-glucuronide was positively associated with fullness. After mycoprotein, creatinine and the deamination product of isoleucine, α-keto-β-methyl-N-valerate, were inversely related to fullness, whereas the ketone body, β-hydroxybutyrate, was positively associated. In conclusion, mycoprotein reduces energy intake and insulin release in overweight volunteers. The mechanism does not involve changes in PYY and GLP-1. The metabonomics analysis may bring new understanding to the appetite regulatory properties of food. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/27198187/Mycoprotein_reduces_energy_intake_and_postprandial_insulin_release_without_altering_glucagon_like_peptide_1_and_peptide_tyrosine_tyrosine_concentrations_in_healthy_overweight_and_obese_adults:_a_randomised_controlled_trial_ L2 - http://journals.cambridge.org/abstract_S0007114516001872 DB - PRIME DP - Unbound Medicine ER -